Key Developments: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,733.00GBp
11:47am EDT
Price Change (% chg)

108.00p (+6.65%)
Prev Close
1,625.00p
Open
1,635.00p
Day's High
1,733.00p
Day's Low
1,627.00p
Volume
611,325
Avg. Vol
243,210
52-wk High
1,832.51p
52-wk Low
1,031.02p

Search Stocks

Latest Key Developments (Source: Significant Developments)

Hikma completes acquisition of Ben Venue manufacturing site
Wednesday, 17 Sep 2014 02:01am EDT 

Hikma Pharmaceuticals Plc:Says that it has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, Inc, part of the Boehringer Ingelheim Group of Companies, as agreed on July 24.Says the Ben Venue site includes four manufacturing plants and a state-of-the-art Quality and Development Centre.  Full Article

Hikma Pharmaceutical Plc declares dividend
Wednesday, 20 Aug 2014 11:00am EDT 

Hikma Pharmaceutical Plc:As previously announced with interim results, company is paying total dividend of 11 cents per share, comprising interim dividend of 7.0 cents and special dividend of 4 cents.Interim and special dividend will be paid on Sept. 26, 2014 to eligible shareholders on register at close of business on Aug. 29, 2014.Ex-dividend date is Aug. 27, 2014 and final date for currency elections is Sept. 12, 2014.  Full Article

Hikma Pharmaceutical Plc declares dividends
Wednesday, 20 Aug 2014 02:01am EDT 

Hikma Pharmaceutical Plc:Declared an interim dividend of 7.0 cents per share (about 4.2 pence per share), in line with 7.0 cents per share for the first half of 2013.In addition, the board has declared a special dividend of 4.0 cents per share (about 2.4 pence per share).The interim dividend and the special dividend will be paid on Oct. 26 to eligible shareholders on the register at the close of business on Aug. 29.The ex-dividend date is Aug. 27 and the final date for currency elections is Sept. 12.  Full Article

Hikma Pharmaceutical Plc reaffirms FY 2014 revenue outlook
Wednesday, 20 Aug 2014 02:00am EDT 

Hikma Pharmaceutical Plc:Continue to expect the Group to deliver full year revenue growth of around 5 pct in FY 2014.Reported revenue of $1.365 bln in FY 2013.  Full Article

Hikma Pharmaceuticals agrees to acquire Ben Venue manufacturing site
Thursday, 24 Jul 2014 04:08am EDT 

Hikma Pharmaceuticals Plc:Agrees with Ben Venue Laboratories to acquire all assets of their generic injectables manufacturing site in Bedford, Ohio.Acquisition pursuant to arrangement entered into on May 28.No incremental consideration payable.Gross assets, subject to transaction prior to performance of fair value exercise and excluding acquired intangible assets, have book value of $4 mln.  Full Article

Hikma Pharmaceuticals PLC completes acquisition of assets
Tuesday, 15 Jul 2014 10:35am EDT 

Hikma Pharmaceuticals PLC:Completes acquisition of assets of US generic injectables business, Bedford Laboratories (Bedford) from Ben Venue Laboratories, Inc., member of Boehringer Ingelheim Group of Companies.As previously announced, total consideration of up to $300 mln will be satisfied through an upfront cash payment of $225 mln.Contingent cash payments of up to $75 mln, subject to achievement of performance-related milestones over a period of five years.  Full Article

Hikma Pharmaceuticals PLC announces acquisition
Wednesday, 28 May 2014 07:00am EDT 

Hikma Pharmaceuticals PLC:Signed an asset purchase agreement with Ben Venue Laboratories Inc to acquire assets of Bedford Laboratories.Its US generic injectables business, for a total consideration of up to $300 million, which will be satisfied through an upfront cash payment of $225 million.A further $75 million in contingent cash payments will be paid, subject to the achievement of performance-related milestones, over a period of five years.In addition, Hikma has entered into an exclusivity arrangement with the Boehringer Ingelheim Group to potentially acquire substantially all of the assets of the Ben Venue manufacturing facility in Bedford, Ohio.  Full Article

Hikma Pharmaceuticals Plc reiterates FY 2014 revenue guidance
Thursday, 15 May 2014 02:00am EDT 

Hikma Pharmaceuticals Plc:Reiterates guidance for FY 2014 of around 5 pct. revenue growth.Reported revenue of $1.365 bln in FY 2013.FY 2014 revenue of $1.436 bln - Thomson Reuters I/B/E/S.  Full Article

Hikma Pharmaceuticals PLC announces resolution to US FDA warning letter at Eatontown facility
Wednesday, 2 Apr 2014 02:00am EDT 

Hikma Pharmaceuticals PLC:Receives close-out letter from the US Food and Drug Administration that lifts the warning letter received in Feb. 2012 in respect of its Eatontown facility in New Jersey, which provides oral products for the US market.This communication follows the US FDA's re-inspection of the facility in Feb. to complete its evaluation of the corrective actions taken in response to the warning letter.This resolves all issues raised by the US FDA in Feb. 2012 and all subsequent communications.  Full Article

Hikma Pharmaceuticals PLC declares dividends
Wednesday, 12 Mar 2014 03:00am EDT 

Hikma Pharmaceuticals PLC:Recommends final dividend of 13.0 cents and special final dividend of 4.0 cents per share.To be paid on May 22 to shareholders on register of close of business on Apr 25.Ex-dividend date is on Apr 23.  Full Article

Search Stocks